• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2018 Fiscal Year Final Research Report

Elucidation of the mechanism of VEGF-B signal-regulated fatty acid uptake in hepatocytes

Research Project

  • PDF
Project/Area Number 17K15963
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Gastroenterology
Research InstitutionWakayama Medical University

Principal Investigator

YAMAGISHI NAOKO  和歌山県立医科大学, 医学部, 助教 (40646840)

Project Period (FY) 2017-04-01 – 2019-03-31
Keywordsランソプラゾール / VEGF-B / 脂肪肝 / NAFLD
Outline of Final Research Achievements

Lansoprazole reduced the expression of VEGF-B mRNA in HepG2 and Hep3B human hepatic cell lines. Some fatty acid transporters were also downregulated by lansoprazole. We investigated the effect of lansoprazole on intracellular lipid accumulation using HepG2 and Hep3B. There was no significant difference in the intracellular fatty acid uptake levels, whereas a marked increase in LDL-cholesterol uptake by lansoprazole. We observed that lansoprazole activated the Liver X receptor (LXR) that is a key transcriptional regulator of cholesterol metabolism in HepG2 and Hep3B cells.

Free Research Field

細胞生物学

Academic Significance and Societal Importance of the Research Achievements

本研究では、胃酸分泌抑制剤であるランソプラゾールが肝細胞の脂質代謝機能に与える影響を明らかにした。我々は以前、ランソプラゾールが非アルコール性脂肪肝疾患(NAFLD)モデルラットの病態進行を遅延させるという新しい薬効の存在を報告しており、本研究成果はランソプラゾールによる脂肪肝抑制メカニズムの一つとして重要な知見となった。NAFLDはメタボリック症候群の原因として知られているが、現時点では脂肪肝を解消する有効な治療薬はなく、ランソプラゾールは有用な脂肪肝治療薬候補と考えられる。

URL: 

Published: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi